Randomized Study of Pregabalin for Pain Reduction in Patients With Rest Pain and Lower Limb Ischemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00403780|
Recruitment Status : Unknown
Verified May 2015 by Jonas Malmstedt, Karolinska Institutet.
Recruitment status was: Recruiting
First Posted : November 27, 2006
Last Update Posted : May 8, 2015
|Condition or disease||Intervention/treatment||Phase|
|Critical Limb Ischemia Arterial Occlusive Disease Pain Ischemia||Drug: pregabalin Drug: placebo||Phase 4|
Critical limb ischemia (CLI) is the end stage of peripheral arterial disease in the legs and is a consequence of deteriorating blood flow supply to the lower limbs. The clinical definition of CLI includes peripheral arterial disease and recurrent rest pain for at least two weeks with or without ulcers or gangrene.
In patients not amenable to revascularization - around 35% - amputation or palliative conservative care remains the options. Pain control is a vital part of any treatment of these patients. Besides being the principal conservative treatment, also patients undergoing revascularization experience severe pain both during work up and after surgery.
Experimental data indicate that pain in CLI is multimodal and to a large extent neuropathic. Still, current therapy is mostly based on opioid treatment, which clinically often affects pain moderately. The doses required to influence pain are also associated to severe side effects. Accordingly, there is a great need to improve pain control in the rather common disease CLI.
comparisons: pregabalin up to 600mg daily in addition to regular pain regimens compared to placebo and regular pain regimens.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Pregabalin for Pain Reduction in Critical Limb Ischemia - A Double Blind, Randomized Controlled Study|
|Study Start Date :||June 2006|
|Estimated Primary Completion Date :||May 2015|
|Estimated Study Completion Date :||July 2015|
Active Comparator: A
Active intervention with pregabalin
Capsule pregabalin 75 mg once or twice daily up to a total dose of 600mg daily (300mg twice daily) for a total of minimum 14 days and maximum 8 weeks.
Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
Other Name: Capsule Lyrica 75mg. Manufacturer company: Pfizer
Placebo Comparator: B
placebo arm with capsule Lyrica Placebo
Capsule placebo once or twice daily up to a total dose of 8 capsules(4 capsules twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
Other Name: Lyrica Placebo
- Reduction in Rating Scale (RS) pain compared to baseline. RS Pain will be assessed at 7, 14 days for all participants and after 28 and 56 days for patients continuing the extended phase of study. [ Time Frame: 1, 2, 4 and 8 weeks after randomization ]
- Improvement in the Short Form 36 (SF-36) parameter "bodily pain". [ Time Frame: This parameter will be evaluated at baseline, after seven and 14 days of treatment. Patients continuing in the study will be scored also at 28 and 56 days. ]
- The amount, dose and duration of concomitant pain medication use during study compared to use before study. [ Time Frame: 2 weeks after randomization ]
- Safety outcomes and adverse events will be examined and recorded throughout the study. Patient reported dizziness will be recorded separately in the CRF, as well as blood pressure at visits. [ Time Frame: up to 8 weeks, as long as patients is in the study. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00403780
|Contact: Eric Wahlberg, MD, PhD||+46 8 517 70000 ext firstname.lastname@example.org|
|Contact: Jonas Malmstedt, MD||+46 8 517 70000 ext email@example.com|
|Deptartment of Vascular Surgery, Sahlgrenska University Hospital||Active, not recruiting|
|Department of Vascular Surgery, Karolinska University Hospital||Recruiting|
|Stockholm, Sweden, SE-171 76|
|Contact: Jonas Malmstedt, MD +46 8 517 70000 ext 6895 firstname.lastname@example.org|
|Principal Investigator: Jonas Malmstedt, MD|
|Sub-Investigator: Ulrika Palmer-Kazen, MD, PhD|
|Deptartment of Surgery, South Hospital||Not yet recruiting|
|Contact: Peter Konrad, MD, PhD|
|Principal Investigator: Peter Konrad, MD, PhD|
|Principal Investigator:||Eric Wahlberg, MD. PhD||Karolinska Institutet|